You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: April 25, 2025

VORAXAZE Drug Profile


✉ Email this page to a colleague

« Back to Dashboard


Summary for Tradename: VORAXAZE
High Confidence Patents:0
Applicants:1
BLAs:1
Recent Clinical Trials: See clinical trials for VORAXAZE
Recent Clinical Trials for VORAXAZE

Identify potential brand extensions & biosimilar entrants

SponsorPhase
Charite University, Berlin, GermanyPhase 1/Phase 2
National Cancer Institute (NCI)Early Phase 1
OHSU Knight Cancer InstituteEarly Phase 1

See all VORAXAZE clinical trials

Pharmacology for VORAXAZE
Established Pharmacologic ClassCarboxypeptidase
Chemical StructureCarboxypeptidases
Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

  1. Brand-side disclosures in response to biosimilar applications
  2. These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

  3. General brand-side disclosures
  4. These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

  5. Patents from broad patent text search
  6. For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for VORAXAZE Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for VORAXAZE Derived from Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for VORAXAZE Derived from Patent Text Search

These patents were obtained by searching patent claims

Market Dynamics and Financial Trajectory for the Biologic Drug: Voraxaze

Introduction

Voraxaze, also known as glucarpidase, is a biologic drug that has revolutionized the treatment of methotrexate toxicity, particularly in patients with impaired renal function. This article delves into the market dynamics and financial trajectory of Voraxaze, highlighting its clinical significance, regulatory approvals, market performance, and future prospects.

Clinical Significance of Voraxaze

Voraxaze is a carboxypeptidase enzyme that rapidly reduces toxic plasma methotrexate concentrations in patients with delayed methotrexate clearance due to renal dysfunction. This is crucial because high-dose methotrexate (MTX) is a common treatment for various cancers, including central nervous system lymphoma (CNSL), but it can lead to severe toxicity if not cleared properly from the body[1][5].

Regulatory Approvals

FDA Approval

Voraxaze was approved by the US FDA in 2012 for the treatment of acute methotrexate toxicity in patients who receive high-dose methotrexate. This approval marked a significant milestone, as it transitioned Voraxaze from emergency use protocols to a fully approved treatment option[2].

EMA Review

In 2020, the European Medicines Agency (EMA) accepted a Marketing Authorisation Application (MAA) for Voraxaze. If approved, this would grant Voraxaze marketing authorization in all EU member states, as well as in Iceland, Liechtenstein, and Norway. This expansion is expected to broaden the drug's reach and impact in the European market[1].

Market Performance

Initial Market Presence

Before its FDA approval, Voraxaze was available in the US under emergency use or special exception protocols. These protocols allowed for cost recovery but did not permit promotional activities. The FDA approval in 2012 was a critical step in expanding its market presence[2].

Revenue Projections

Protherics, the initial developer of Voraxaze, estimated that the market for Voraxaze could be worth $25-50 million per annum. Following its acquisition by BTG Specialty Pharmaceuticals, the drug has seen significant revenue growth. BTG's financial reports indicate that Voraxaze, along with other specialty pharmaceuticals, has contributed to the company's revenue growth, with projected annual sales growth of 15% over the medium term[4].

Competitive Landscape

Voraxaze operates in a niche market focused on treating methotrexate toxicity. Its unique mechanism of action and rapid efficacy make it a standout in this space. However, the market is not without competition, as other antidotes for chemotherapy toxicity, such as uridine triacetate for 5-FU toxicity, also exist. Despite this, Voraxaze's specific indication and proven efficacy have secured its position as a critical treatment option[2].

Financial Trajectory

Revenue Growth

Since its FDA approval, Voraxaze has contributed significantly to BTG Specialty Pharmaceuticals' revenue. In 2012, BTG reported revenues at the upper end of their guidance, partly due to the contribution from Voraxaze. The company projected continued growth, with Voraxaze being a key driver in their specialty pharmaceuticals segment[2].

Market Expansion

The potential EMA approval and subsequent marketing authorization in the EU are expected to further boost Voraxaze's revenue. This expansion into the European market will increase the drug's accessibility and usage, contributing to higher sales figures[1].

Cost and Pricing

The cost of Voraxaze is significant due to its biologic nature and the complexity of its production. However, the drug's ability to rapidly reduce methotrexate levels and prevent severe toxicity justifies its cost. Hospitals and healthcare systems often prioritize treatments that can reduce long-term healthcare costs and improve patient outcomes, making Voraxaze a valuable investment despite its higher upfront cost[5].

Clinical Studies and Real-World Experience

Efficacy Studies

Clinical trials, including four open-label multi-center studies, have demonstrated Voraxaze's efficacy in reducing methotrexate concentrations. In these studies, a median reduction of over 98% in methotrexate concentration was observed within 15 minutes of Voraxaze administration. Real-world experience in the US has supported these findings, with over 2,867 patients treated with Voraxaze since its launch[1].

Outpatient Treatment Feasibility

Recent studies have explored the feasibility of using Voraxaze to enable outpatient high-dose MTX treatment, particularly during the COVID-19 pandemic. These studies indicate that Voraxaze can safely reduce serum methotrexate levels in outpatient settings, reducing the need for hospital admissions and thereby alleviating pressure on healthcare resources[5].

Safety and Precautions

Serious Hypersensitivity Reactions

While Voraxaze is highly effective, it is not without risks. Serious hypersensitivity reactions are a significant concern, and patients must be closely monitored for any adverse reactions. Additionally, Voraxaze is not recommended for patients who exhibit expected methotrexate clearance, as reducing plasma methotrexate levels in these patients could result in subtherapeutic exposure to methotrexate[1][5].

Future Prospects

Market Expansion and Penetration

The potential approval by the EMA and the ongoing studies exploring outpatient treatment options are expected to drive further market penetration and expansion. As more clinicians become aware of Voraxaze's benefits, its usage is likely to increase, contributing to higher revenues and a stronger market presence.

Continued Research and Development

Ongoing and future studies will continue to characterize the drug-drug interactions and the long-term safety profile of Voraxaze. This research will be crucial in solidifying its position as a first-line treatment for methotrexate toxicity and potentially expanding its indications.

Key Takeaways

  • Regulatory Approvals: Voraxaze has been approved by the FDA and is under review by the EMA for marketing authorization in the EU.
  • Clinical Significance: It rapidly reduces toxic plasma methotrexate concentrations, making it a critical treatment for patients with impaired renal function.
  • Market Performance: Voraxaze has contributed significantly to BTG Specialty Pharmaceuticals' revenue and is projected to continue growing.
  • Safety and Precautions: Serious hypersensitivity reactions are a concern, and the drug is not recommended for patients with expected methotrexate clearance.
  • Future Prospects: Potential EMA approval and ongoing studies are expected to drive market expansion and penetration.

FAQs

What is Voraxaze used for?

Voraxaze is used to reduce toxic plasma methotrexate concentrations in adult and pediatric patients with delayed methotrexate clearance due to impaired renal function.

When was Voraxaze approved by the FDA?

Voraxaze was approved by the FDA in February 2012 for the treatment of acute methotrexate toxicity.

What are the potential side effects of Voraxaze?

Serious hypersensitivity reactions are a significant concern with Voraxaze administration.

Can Voraxaze be used in outpatient settings?

Yes, recent studies have shown the feasibility of using Voraxaze to enable outpatient high-dose MTX treatment, reducing the need for hospital admissions.

What is the estimated market value of Voraxaze?

The estimated market value of Voraxaze is between $25-50 million per annum.

Sources

  1. European Medicines Agency has accepted for review a marketing authorisation application for Voraxaze - SERB.
  2. Outlook Investment summary: Data support upgrade - Edison Investment Research.
  3. Voraxaze 2021 U.S. PROMOTIONAL AUDIT REPORT - MDDetails.
  4. Critical|Care - Annual Reports - Protherics PLC Annual Report 2008.
  5. Initial study results show feasibility of outpatient methotrexate administration with planned use Voraxaze during COVID-19 pandemic - SERB.

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.